Patient Medication Instructions: Detailed explanation of the role and efficacy of tepotinib

Tepotinib is a targeted therapy drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations (METex14). The MET gene is a common receptor tyrosine kinase gene that plays an important role in various physiological processes such as cell growth, differentiation and survival. In non-small cell lung cancer, MET gene mutations, especially MET exon 14 skipping mutations, can lead to abnormal activation of MET protein, thereby promoting tumor growth and metastasis. Therefore, tepotinib prevents the proliferation and spread of cancer cells by selectively inhibiting the activity of MET tyrosine kinase.

The mechanism of action of Tepotinib is by binding to the ATP binding site of the MET receptor, thereby inhibiting its kinase activity, avoiding the activation of downstream signaling pathways, and ultimately achieving the effect of inhibiting the growth of tumor cells. Unlike other traditional chemotherapy drugs, tepotinib is a precision targeted therapy drug that can intervene on specific molecular mutations, so its side effects are more controllable than chemotherapy drugs.

Clinical studies have shown that tepotinib has shown significant efficacy in the treatment of non-small cell lung cancer patients with METex14 mutations. According to the VANISH trial data, the objective response rate (ORR) of tepotinib is as high as more than 50%, and the median response duration is also relatively ideal. These data show that tepotinib provides a new treatment option for patients with METex14 mutations who are ineffective or resistant to conventional chemotherapy.

In summary, tepotinib is a targeted drug targeting MET gene mutations. It effectively inhibits the progression of non-small cell lung cancer by inhibiting MET receptor kinase activity. It has significant efficacy, especially for patients carrying MET exon 14 skipping mutations. As a precision treatment drug, the emergence of tepotinib brings new hope for treatment of lung cancer patients related to MET abnormalities.

Reference materials:https://www.tepotinib.com/